Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus AI (TEM) announced acceptance of 13 abstracts for presentation at the ESMO Congress, taking place October 23–27, 2026, in Madrid.
The research covers cancer biology, treatment response and patient outcomes across several solid tumors. Topics include prostate cancer, early-onset breast cancer, ovarian cancer associated with ATM mutations, and outcomes with trastuzumab deruxtecan in advanced gynecologic malignancies. Other presentations address AI-enabled lung cancer pre-screening using pathology images and interim results of the multicenter LOLA Project on blood-based genomic testing. Scheduled presentations run October 23, 25 and 26, alongside two e-posters.
Tempus AI (TEM) received FDA 510(k) clearance for ECG-MR, software that flags signs associated with undiagnosed moderate or severe mitral regurgitation.
The fourth FDA-cleared Tempus ECG-AI product analyzes resting 12-lead electrocardiograms, or ECGs, and gives a binary output to help identify patients for further evaluation, such as diagnostic imaging. Mitral regurgitation occurs when blood leaks backward through the mitral valve. The software is intended for clinical diagnostic ECGs recorded at a healthcare facility from patients aged 65 or older who are at risk of cardiovascular disease, have had no mitral valve intervention and have no prior diagnosis of moderate or severe mitral regurgitation.
It is not a stand-alone diagnostic tool or for serial monitoring, and it should not be used on ECGs with paced rhythms. Results should be read alongside the original ECG, other tests, symptoms and clinical history.
Tempus AI (TEM) and Recursion Pharmaceuticals (RXRX) have extended their multi-year data license agreement and signed a new RNA foundation model license. The collaboration, first established in 2023, is now extended through November 2029.
As part of the extension, the parties amended the Annual License Fees under their Master Agreement, replacing discretionary license fees potentially totaling $84 million over the next two years with committed payments totaling $42 million over the next three years. Separately, Recursion granted Tempus a non-exclusive, worldwide license to its proprietary RNA sequencing model, “TxFM”, under a new license agreement, supporting both companies’ efforts to apply foundation models to precision medicine.
Tempus AI (TEM) announced a multi‑year initiative to build a research platform containing 100,000 disease‑specific whole‑genome sequences linked to longitudinal clinical information, with a long‑term goal of scaling to 1 million genomes.
The company describes this as the first de‑identified multimodal whole‑genome sequencing dataset centered on disease populations and patient outcomes, optimized for AI research. The new whole‑genome sequencing data will be integrated into Tempus’ existing multimodal environment, combining genomics with clinical histories, imaging, pathology and outcomes. Through the Tempus Lens platform, researchers and model developers will be able to analyze the data and build or validate AI models within a model‑ready environment. Development is underway, an initial dataset is accessible via an Early Adopter Program, and broader availability is planned for mid‑2027.
Tempus AI (TEM) has been selected by ARPA-H’s ADVOCATE program to receive up to $9.5 million to develop an autonomous clinical AI agent for heart failure care.
The funding from the U.S. health research agency will support both product development and clinical validation in a multi-center prospective study. The AI agent is intended to function as an extension of clinician teams, coordinating 24-hour cardiovascular care without direct human intervention. Tempus plans to integrate continuous data from electronic health records and home-based heart rate monitors and to build on its existing AI portfolio, including Olivia, Tempus Next, and three FDA-cleared ECG-AI products.
Tempus (TEM)/b) will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. ET in New York City.Founder and CEO Eric Lefkofsky will represent the company, and a live audio webcast of the conversation will be available online.
Tempus AI (NASDAQ: TEM) received U.S. FDA 510(k) clearance for Tempus ECG-PH, an AI-enabled software device that analyzes standard resting 12-lead ECGs for signs associated with pulmonary hypertension (PH), defined as elevated mean pulmonary artery pressure (mPAP > 20 mmHg).
ECG-PH is Tempus’ third FDA-cleared cardiovascular AI product, joining tools for atrial fibrillation and low ejection fraction, and targets adults aged 40+ with cardiovascular symptoms and no known PH. The software provides a binary output and is intended to support, not replace, traditional diagnostic methods such as right heart catheterization and echocardiography, with results to be interpreted alongside other clinical information.
CellCarta announced a strategic collaboration with Tempus AI (NASDAQ: TEM), adding Tempus as the second commercial laboratory partner in CellCarta's CDx Commercialization Lab Network, alongside Sonic Healthcare USA. The partnership focuses on oncology and aims to streamline the path from companion diagnostic (CDx) development and regulatory approval to commercial use in U.S. oncology practice.
According to CellCarta, Tempus will use Tempus Hub to support provider test ordering, route samples to CellCarta for testing, and return results to physicians. The Lab Network is a component of CellCarta's four-stage CDx Accelerator Model (Build, Validate, Launch, Transfer), designed to give biopharma sponsors flexible entry points and commercialization pathways for centralized oncology CDx.
Tempus AI (NASDAQ: TEM) reported that a study in Nature Medicine demonstrates its multimodal slide-level pathology foundation model PRISM2, developed with Microsoft researchers, can perform clinically important diagnostic tasks via simple prompts and support multiple downstream applications.
According to Tempus, PRISM2 outperformed or matched existing slide-level foundation models across diagnostic, biomarker, and patient outcome prediction tasks, and, when tuned for survival, exceeded standalone models in predicting colorectal cancer recurrence-free survival. The model was trained on 2.3 million whole-slide images and 14 million diagnostic question–answer pairs from nearly 700,000 pathology reports, and its full weights are publicly available on Hugging Face for non-commercial, non-clinical use.
Tempus (NASDAQ: TEM) reported Q2 2026 revenue of $382.5 million, up 22% year-over-year, with Diagnostics at $289.3 million (+20%) and Data and Applications at $93.2 million (+28%, Insights +36%). Gross profit rose 26% to $246.5 million.
The company recorded GAAP net income of $5.6 million versus a $42.8 million loss a year ago and Adjusted EBITDA of $8.0 million versus a $5.6 million loss. Tempus ended the quarter with $820.7 million in cash and marketable securities and completed a $460 million 0.0% convertible notes offering due 2032.
Tempus entered a definitive agreement to acquire Personalis for $16.25 per share (~$1.5 billion enterprise value) and secured FDA approval for its xT tumor-only CDx assay. The company raised 2026 revenue guidance to $1.595–$1.605 billion and reiterated expected full-year Adjusted EBITDA of ~$65 million.